$ARVN

Arvinas, Inc. (ARVN) presented Phase 1 trial data for ARV-102, a PROTAC degrader targeting LRRK2, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. The study showed dose-dependent improvements in eye movement and biomarker changes in Parkinson’s patients, supporting further evaluation. ARV-102 is being developed for neurodegenerative diseases associated with LRRK2 dysregulation.

Arvinas (ARVN) will present Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. ARV-102 targets LRRK2, a protein linked to Parkinson’s and PSP. The presentations will include biomarker and oculomotor data. Arvinas is a clinical-stage biotech company focused on protein degradation therapies.

Arvinas Inc. (ARVN) began a Phase 1/2 trial for ARV-6723, a PROTAC targeting HPK1 in advanced solid tumors. The global study will assess safety, pharmacokinetics, and antitumor activity as a monotherapy and with pembrolizumab. Preclinical data showed potent HPK1 degradation and antitumor effects. ARVN stock closed at $7.59, up 0.13% in pre-market trading.

Arvinas (ARVN) reported Q2 2026 revenue of $249.7M, up from $22.4M a year earlier, driven by FDA approval of VEPPANU and a licensing deal with Rigel. The FDA approved VEPPANU, the first PROTAC therapy, for advanced breast cancer. Arvinas licensed global rights to Rigel, generating $50M in milestone revenue and $62.5M in license revenue. The company expects three Phase 1 readouts in the next year. Cash reserves fell to $567.9M from $685.4M due to operational expenses.

Arvinas (ARVN) reported Q2 2026 revenue of $249.7 million, including $62.5 million from a Rigel license and a $50 million Pfizer (PFE) milestone tied to FDA approval of VEPPANU. Net income was $169.4 million and diluted EPS $2.58. Cash and marketable securities were $567.9 million, funding into 2H 2028. The call also discussed clinical timing updates and an FDA-requested delay for ARV-102.

Morgan Stanley lowered its price target on Arvinas, Inc. to $10 from $11 and kept an Equalweight rating, according to the note cited in the article. The stock was shown at about $8.75 at the time of publication.

Arvinas shares rose 13.2% after the company reported Q2 2026 results before the open. EPS was $2.58 versus a forecast loss of $0.38, and revenue was $249.7 million versus $58.61 million expected, including licensing and milestone items tied to VEPPANU and Rigel. Management cited VEPPANU approval, upcoming Phase 1 data, and a cash runway into H2 2028.

ARVINAS, INC. (ARVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals –

ARVINAS, INC. (ARVN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. arvn-20260624 0001655759 FALSE 0001655759 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________ FORM 8-K __________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Rep

ARVINAS, INC. (ARVN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. arvn-20260622 0001655759 FALSE 0001655759 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________ FORM 8-K __________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Rep